Table 3 Cardiovascular adverse events following BiTE therapy

From: Cardiovascular complications of cellular immunotherapies and associated risk factors

Study

Population

Sample size

BiTE product

Heart failure (%)

Arrhythmia, N (%)

ACS/MI, N (%)

Myocarditis N(%)

Cardiac death N(%)

Other N(%)

Jung, et al.56

B-ALL

50

Blinatumomab

N/A

N/A

N/A

N/A

N/A

Unspecified CVAE: 7 (14.0%)

Sayed, et al. 202455

B-ALL, NHL, & MM

3668

Blinatumomab, Teclistamab, Glofitamab, Mosunetuzumab, Epocritamab

52 (1.4%)

32 (0.9%)

16 (0.4%)

8 (0.2%)

2 (0.05%)

N/A

  1. ACS acute coronary syndrome, B-ALL B-cell acute lymphocytic leukemia, BiTE bispecific T-cell engager, CVAE cardiovascular adverse event, MI myocardial infarction, MM multiple myeloma, NHL non-Hodgkins lymphoma.
Back to article page